Cowen Upgrades Novartis To Outperform

Analysts at Cowen & Company upgraded

from Market Perform to Outperform. The price target for Novartis has been raised from $95 to $105. Novartis shares have surged 16.49% over the past 52 weeks, while the S&P 500 index has gained 12.67% in the same period. Novartis' shares fell 0.44% to close at $92.25 on Friday.